ReviewBiomarkers in medicine2011
Biomarkers to optimize the treatment of nicotine dependence.
Review in Biomarkers in medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Tobacco Use Disorder.The Medical clinics of North America · 2022Review
- Rationale and design of a randomized factorial clinical trial of pharmacogenetic and adherence optimization strategies to promote tobacco cessation among persons with HIV.Contemporary clinical trials · 2021Article
- Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016Review
- Alternative Sampling Strategies for Cytochrome P450 Phenotyping.Clinical pharmacokinetics · 2016Review
- Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers.Addictive behaviors · 2015Article
- Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.Addiction science & clinical practice · 2014Review
- The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race.Psychopharmacology · 2014Article
- Genetic analysis of polymorphisms in dopamine receptor and transporter genes for association with smoking among cancer patients.European addiction research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
The application of genomic medicine to the treatment of nicotine dependence holds great promise for revitalizing the steady decline in smoking rates witnessed in the USA over the past several decades. This paper examines the current knowledge base concerning the use of biomarkers to guide the selection of nicotine dependence treatments. First, we review the neurobiology of nicotine dependence and present evidence that supports its heritability. We then discuss the various studies of pharmacokinetic and pharmacodynamic genes related to therapeutic response. Current evidence suggests that biomarkers of genetic variability in both nicotine metabolism, referred to as the nicotine metabolite ratio, and dopamine genotypes may be useful for guiding treatment selection for nicotine dependence. Barriers to the translation of this research to clinical practice are discussed, as are directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.